Regulus Therapeutics Inc (NASDAQ:RGLS) shares rose 5.6% during mid-day trading on Friday . The stock traded as high as $0.95 and last traded at $0.95. Approximately 1,521,063 shares traded hands during trading, an increase of 76% from the average daily volume of 864,576 shares. The stock had previously closed at $0.90.

RGLS has been the subject of several recent analyst reports. Zacks Investment Research upgraded Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $1.50 target price for the company in a research report on Tuesday, October 10th. Needham & Company LLC reiterated a “hold” rating on shares of Regulus Therapeutics in a report on Tuesday, November 14th. Finally, Wedbush reiterated an “outperform” rating and issued a $4.00 price target on shares of Regulus Therapeutics in a report on Monday, December 11th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and two have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $2.60.

The company has a current ratio of 6.77, a quick ratio of 6.77 and a debt-to-equity ratio of 0.41.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. GSA Capital Partners LLP boosted its holdings in shares of Regulus Therapeutics by 44.8% in the third quarter. GSA Capital Partners LLP now owns 203,815 shares of the biopharmaceutical company’s stock valued at $255,000 after purchasing an additional 63,100 shares during the period. South Dakota Investment Council boosted its holdings in shares of Regulus Therapeutics by 37.1% in the third quarter. South Dakota Investment Council now owns 1,820,027 shares of the biopharmaceutical company’s stock valued at $2,275,000 after purchasing an additional 492,969 shares during the period. Candriam Luxembourg S.C.A. purchased a new stake in shares of Regulus Therapeutics in the third quarter valued at approximately $750,000. NEA Management Company LLC purchased a new stake in shares of Regulus Therapeutics in the third quarter valued at approximately $13,737,000. Finally, Victory Capital Management Inc. bought a new position in Regulus Therapeutics in the third quarter worth approximately $347,000. Hedge funds and other institutional investors own 59.41% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece of content was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/regulus-therapeutics-rgls-stock-price-up-5-6/1769847.html.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.